Budd-Chiari syndrome managed with percutaneous recanalization: Long-term outcome and comparison with medical therapy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: To compare the outcomes in a group of patients with Budd-Chiari syndrome (BCS) managed by percutaneous recanalization with a group of patients who were managed by medical therapy alone.Methods: We retrieved the hospital records of 37 patients with BCS admitted to our facility between 2004 to 2017 and identified 24 patients (male:female = 10:14; mean age, 32.7 ± 12.5 years) who underwent percutaneous recanalization. Remaining thirteen patients (male:female = 3:10; mean age, 36.77 ± 14.71 years), were managed by medical therapy. Technical and clinical results, complications, and primary patency of percutane-ous recanalization were analyzed. Overall and symptom-free survival rates, the frequency of symptom recurrence, and the number of readmissions for recurrent symptoms were analyzed in both interventional treatment and medical therapy groups.Results: Technical success for recanalization of hepatic vein/inferior venecava by angioplasty ± stenting was achieved in 22 patients (22/24, 91.7%). Clinical success was achieved in 19 patients (19/24, 79.2%). Overall survival for patients who underwent percutaneous recanalization at 1 year and five years was 87.0% and 87.0% and for patients with medical therapy was 90.1% and 45.5%, respectively (P = 0.710). Symptom-free survival for patients who underwent percutaneous recanalization at 1 year and five year was 93.3% and 81.7% and for patients with medical therapy was 26.0% and 0%, respectively (P < 0.001). In the intervention group, 4 patients (4/24, 16.7%) were admitted for recurrent symptoms (median number of read-missions 1, range: 1–2) whereas in medically managed patients 9 patients (9/13, 69.2%) were readmitted (median number of readmissions, 2; range, 1–5) (P = 0.003).Conclusion: There was no statistically significant difference in overall survival of patients managed with percutaneous recanalization and medical therapy. Percutaneous recanalization had definite benefit in terms of fewer recurrent symptoms and hospital admissions, hence should be performed whenever technically feasible.
Abstract
Background: To compare the outcomes in a group of patients with Budd-Chiari syndrome (BCS) managed by percutaneous recanalization with a group of patients who were managed by medical therapy alone.Methods: We retrieved the hospital records of 37 patients with BCS admitted to our facility between 2004 to 2017 and identified 24 patients (male:female = 10:14; mean age, 32.7 ± 12.5 years) who underwent percutaneous recanalization. Remaining thirteen patients (male:female = 3:10; mean age, 36.77 ± 14.71 years), were managed by medical therapy. Technical and clinical results, complications, and primary patency of percutane-ous recanalization were analyzed. Overall and symptom-free survival rates, the frequency of symptom recurrence, and the number of readmissions for recurrent symptoms were analyzed in both interventional treatment and medical therapy groups.Results: Technical success for recanalization of hepatic vein/inferior venecava by angioplasty ± stenting was achieved in 22 patients (22/24, 91.7%). Clinical success was achieved in 19 patients (19/24, 79.2%). Overall survival for patients who underwent percutaneous recanalization at 1 year and five years was 87.0% and 87.0% and for patients with medical therapy was 90.1% and 45.5%, respectively (P = 0.710). Symptom-free survival for patients who underwent percutaneous recanalization at 1 year and five year was 93.3% and 81.7% and for patients with medical therapy was 26.0% and 0%, respectively (P < 0.001). In the intervention group, 4 patients (4/24, 16.7%) were admitted for recurrent symptoms (median number of read-missions 1, range: 1–2) whereas in medically managed patients 9 patients (9/13, 69.2%) were readmitted (median number of readmissions, 2; range, 1–5) (P = 0.003).Conclusion: There was no statistically significant difference in overall survival of patients managed with percutaneous recanalization and medical therapy. Percutaneous recanalization had definite benefit in terms of fewer recurrent symptoms and hospital admissions, hence should be performed whenever technically feasible.
참고문헌 (23)
- Valla DC, "Primary Budd-Chiari syndrome", J Hepatol, 50, pp.195~203 (2009)
- Valla DC, "Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West", J Gastroenterol Hepatol, 19, pp.S204~S211 (2004)
- Plessier A, "Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome", Hepatology, 44, pp.1308~1316 (2006)
- Qi XS, "Selection of treatment modalities for Budd-Chiari syndrome in China : a preliminary survey of published literature", World J Gastroenterol, pp.10628~10636 (2014)
- Darwish Murad S, "Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome", Hepatology, 39, pp.500~508 (2004)
- DeLeve LD, "Vascular disorders of the liver", Hepatology, 49, pp.1729~1764 (2009)
- European Association for the Study of the Liver, "EASL clinical practice guidelines:vascular diseases of the liver", J Hepatol, 64, pp.179~202 (2016)
- Griffith JF, "Radiological intervention in Budd-Chiari syndrome : techniques and outcome in 18 patients", Clin Radiol, 51, pp.775~784 (1996)
- Sacks D, "Society of Interventional Radiology clinical practice guidelines", J Vasc Interv Radiol, 14, pp.S199~S202 (2003)
- Dilawari JB, "Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature", Medicine (Baltimore), 73, pp.21~36 (1994)
- Mohanty D, "Hereditary thrombophilia as a cause of Budd-Chiari syndrome : a study from Western India", Hepatology, 34, pp.666~670 (2001)
- Kumar SI, "Low frequency of factor V Leiden and prothrombin G20210A mutations in patients with hepatic venous outflow tract obstruction in northern India : a case-control study", Indian J Gastroenterol, 24, pp.211~215 (2005)
- Eapen CE, "Changing profile of Budd Chiari syndrome in India", Indian J Gastroenterol, 26, pp.77~81 (2007)
- Terabayashi H, "Transformation of inferior vena caval thrombosis to membranous obstruction in a patient with the lupus anticoagulant", Gastroenterology, 91, pp.219~224 (1986)
- Han G, "Percutaneous recanalization for Budd-Chiari syndrome : an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center", Radiology, 266, pp.657~667 (2013)
- Garcia-Pagán JC, "TIPS for Budd-Chiari syndrome : long-term results and prognostics factors in 124 patients", Gastroenterology, 135, pp.808~815 (2008)
- Mentha G, "Liver transplantation for Budd-Chiari syndrome : a European study on 248 patients from 51 centres", J Hepatol, 44, pp.520~528 (2006)
- Jagtap N, "Budd-Chiari syndrome : outcomes of endovascular intervention-A single-center experience", Indian J Gastroenterol, 36, pp.209~216 (2017)
- Tripathi D, "Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome", Liver Int, 37, pp.111~120 (2017)
- Cui YF, "Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome : long-term patency and survival", Hepatol Int, 10, pp.363~369 (2016)
- Zhang W, "Budd-Chiari syndrome in China : a 30-year retrospective study on survival from a single center", World J Gastroenterol, 24, pp.1134~1143 (2018)
- Zeitoun G, "Outcome of Budd-Chiari syndrome : a multivariate analysis of factors related to survival including surgical portosystemic shunting", Hepatology, 30, pp.84~89 (1999)
- Darwish Murad S, "Etiology, management, and outcome of the Budd-Chiari syndrome", Ann Intern Med, 151, pp.167~175 (2009)